DeCure's autonomous Rare AI scientist is researching a drug-repurposing hypothesis for achondrogenesis — screening already-approved drugs against its 3-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease moduleAchondrogenesis maps to a 3-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for achondrogenesis is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
Molecular view
collagen type II alpha 1 chain (COL2A1) — COL2A1 is one of the genes genetically linked to this disease in Open Targets — shown as context, not as a drug target we're pursuing: no approved-drug candidate for this disease is yet corroborated in the literature we found.
Loading structure…
helix sheet p33drag to rotate · scroll to zoom
RCSB Protein Data Bank · entry 5NIR · 1.74 Å · ligand 3,6,9,12,15,18-HEXAOXAICOSANE-1,20-DIOL (P33). Experimental structure, not a prediction.
What the evidence adds up to
Achondrogenesis type 2 is a lethal skeletal disorder caused by a dominant mutation in the COL2A1 gene. In one family, two pregnancies from the same couple showed gross, radiologic, and microscopic findings of achondrogenesis type 2. Molecular analysis of the second infant found heterozygosity for a c.2303G > A transition (p.Gly768Asp) in exon 33 of the COL2A1 gene. The mutation could not be proven by molecular studies in the first infant, but the identical findings in two affected pregnancies support germline mosaicism as the cause in that family.
Achondrogenesis is a rare form of lethal dwarfism, usually discovered after birth, with only a few instances of diagnosis in the uterus reported by 1977. In another report from 1976, two male siblings with a severe and lethal form of micromelic dwarfism had clinical, pathological, and radiological features suggesting achondrogenesis type 1, but the markedly deficient ossification of the skull and the presence of intrauterine rib fractures were atypical. Similar changes had been observed in two other families with two or more infants with suspected achondrogenesis, raising the possibility that these familial cases may be a subvariant of achondrogenesis or a distinct disease entity. The disease appeared to be inherited as an autosomal recessive, and death occurred shortly after birth because of severe pulmonary hypoplasia.
No drug treatment is mentioned in any of these abstracts. There is no evidence of any intervention that alters the course of the disease. The abstracts describe only the genetic and pathological characterisation of the condition.
What is missing is any preclinical or clinical research into treatments, any funding for drug development, any trial design, and any patient stratification beyond the genetic subtyping described. No repurposing candidate has been tested or proposed in the available literature.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
American Journal of Medical Genetics Part A · 2010 · 24 citations
Recurrence of achondrogenesis type 2 in sibs: Additional evidence for germline mosaicism
AbstractAchondrogenesis Type II (ACG2) is a lethal skeletal disorder caused by a dominant mutation in the type II collagen gene (COL2A1). Familial cases have been reported, suggesting both germline and somatic mosaicism. We report on two pregnancies from the same couple with gross, radiologic, and microscopic findings of ACG2. Molecular analysis of the second infant demonstrated heterozygosity for a c.2303G > A transition (p.Gly768Asp) in exon 33 of the COL2A1 gene. Although this mutation could not be proven by molecular studies in the first infant, identical findings in two affected pregnancies support germline mosaicism as the cause of ACG2 in this family.
RöFo - Fortschritte auf dem Gebiet der Röntgenstrahlen und der bildgebenden Verfahren · 1977 · 10 citations
Achondrogenesis, Type I
AbstractAchondrogenesis ist eine seltene Art von tödlichem Zwergwuchs. Normalerweise wird sie nach der Geburt entdeckt; nur in einigen Fällen wurde sie im Uterus erkannt. Einer dieser Fälle wird hier zusammen mit der Differentialdiagnose von Achondrogenesis und den anderen Formen von tödlichem Zwergwuchs beschrieben. Zusammenfassung Achondrogenesis is a rare form of lethal dwarfism. Usually discovered post partum, in a few instances only it has been diagnosed in utero. One such a case is here presented together with differential diagnosis with other forms of lethal dwarfism.
Archives of Disease in Childhood · 1976 · 10 citations · open access
Achondrogenesis type I. A familial subvariant?
AbstractThe clinical, pathological, and radiological features of 2 male sibs with a severe and lethal form of micromelic dwarfism are desribed. The family also includes 2 normal sibs. The histological and radiological appearances suggested a diagnosis of achondrogenesis type I, but the markedly deficient ossification of the skull and the presence of intrauterine rib fractures were atypical. These changes have been observed in two other families with 2 or more infants with suspected achondrogenesis, raising the possibility that these familial cases may be a subvariant of achondrogesis or even a distinct disease entity. The disease appears to be inherited as an autosomal recessive and death occurs shortly after birth because of severe pulmonary hypoplasia.
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
